• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Herz >Effect of levosimendan in patients with acute decompensated heart failure A meta-analysis
【24h】

Effect of levosimendan in patients with acute decompensated heart failure A meta-analysis

机译：Levosimendan在急性失代偿心力衰竭患者中的影响META分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Acute decompensated heart failure (ADHF) is associated with high morbidity and mortality. Intravenous inotropic agents play an important role in treating ADHF. Relatively small clinical studies have evaluated the effects of levosimendan, a positive inotropic agent with calcium-sensitizing effects, in ADHF. The present meta-analysis pooled these studies to assess the clinical efficacy of levosimendan in ADHF. Materials and methods The PubMed, MEDLINE, Cochrane Library, and ClinicalTrials.com databases were systematically searched for prospective clinical studies published in English up to May 2017 on effects of levosimendan alone or versus other agents (placebo [glucose], dopamine, furosemide) on left ventricular ejection fraction (LVEF), brain natriuretic peptide (BNP) level, and heart rate (HR) in patients with ADHF. Results Seven articles were selected with 132 patients for levosimendan and 125 patients for control groups. Compared with controls (except dopamine) or after vs. before use, levosimendan was associated with a significantly reduced BNP level (standardized mean difference [SMD]: -0.70; 95% confidence interval [CI]: -0.92, -0.48; p = 0.000; I-2= 22.0%), as well as improved LVEF (SMD: 0.47; 95%CI: 0.12, 0.81; p= 0.008; I (2)= 63.3%) and increased HR (SMD: 0.39; 95% CI: 0.15, 0.63; p = 0.002; I-2 = 23.6%) when comparing after vs. before use but not in comparisons to controls. Conclusion In the present meta-analysis, levosimendan infusion in patients with ADHF appeared to reduce BNP regardless of the comparator (except for dopamine), and also improve LVEF and increase HR in after vs. before use comparisons but not compared to controls. Future larger studies on the benefit of levosimendan in ADHF patients are warranted.
机译：背景技术急性失代偿性心力衰竭（ADHF）与高发病率和死亡率有关。静脉内渗透剂在治疗ADHF中发挥着重要作用。相对较小的临床研究评估了左旋蛋白酶患者，左右滴度具有钙敏化作用的作用，在ADHF中。目前的荟萃分析汇集了这些研究，以评估左旋蒿在ADHF中的临床疗效。物料和方法在系统地上搜索了PubMed，Medline，Cochrane图书馆和ClinicalTrials.com数据库，达到2017年5月在英语中发表的前瞻性临床研究，仅对Levosimendan独自或与其他药剂（安慰剂γ，多巴胺，呋塞米）的影响进行了影响ADHF患者左心室喷射分数（LVEF），脑利钠肽（BNP）水平和心率（HR）。结果132例左索亚曼丹患者和125例对照组患者选择了7篇文章。与对照组（多巴胺除外）或在使用前和使用前比较，Levosimendan与BNP水平显着降低（标准化平均值[SMD]：-0.70; 95％置信区间[CI]：-0.92，-0.48; P = 0.000; I-2 = 22.0％），以及改进的LVEF（SMD：0.47; 95％CI：0.12,0.81; P = 0.008; I（2）= 63.3％）和HR增加（SMD：0.39; 95％ CI：0.15,0.63; p = 0.002; I-2 = 23.6％）在使用之前进行比较，但在使用之前但不与控制进行比较。结论在目前的荟萃分析中，无论比较器（多巴胺除外），ADHF患者的左旋蛋白酶输注似乎减少了BNP，并在使用比较之前改善了LVEF并增加了HR。有必要对未来大型研究左右左右百年患者的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号